Revisiting risk stratification in hypertrophic cardiomyopathy: Do we need to start from scratch?

摘要

While the majority of those with hypertrophic cardiomy-opathy (HCM) will remain asymptomatic, a significant subset will suffer the devastating complication of sudden cardiac death (SCD). It is difficult to disagree with the notion that implantable cardioverter-defibrillator (ICD) therapy is warranted for secondary prevention after cardiac arrest or sustained ventricular tachyarrhythmia in HCM, but the implantation of an ICD for primary prevention is more controversial as a result of competing risks. Rigorous prediction of the risk of SCD remains the major challenge for those caring for individuals or families with HCM.